Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
10.6M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
1.78M
-
Shares change
-
-2.34M
-
Total reported value, excl. options
-
$392K
-
Value change
-
-$724K
-
Number of buys
-
7
-
Number of sells
-
-6
-
Price
-
$0.22
Significant Holders of Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) as of Q2 2023
23 filings reported holding ARDS - Aridis Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.78M shares
of 10.6M outstanding shares and own 16.81% of the company stock.
Largest 10 shareholders include COMMONWEALTH EQUITY SERVICES, LLC (646K shares), Roumell Asset Management, LLC (447K shares), STATE STREET CORP (202K shares), GEODE CAPITAL MANAGEMENT, LLC (143K shares), VANGUARD GROUP INC (136K shares), HRT FINANCIAL LP (73.7K shares), ACADIAN ASSET MANAGEMENT LLC (36.5K shares), NORTHERN TRUST CORP (28.1K shares), Cornerstone Wealth Management, LLC (20K shares), and Tower Research Capital LLC (TRC) (16.4K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.